6/2/2006

An FDA staff report says Bristol-Myers Squibb's cancer drug dasatinib appears to slow certain types of leukemia in patients who have not responded to other treatments, such as Novartis' Gleevec. An FDA advisory panel is scheduled to meet today to consider recommending approval of dasatinib for treatment of patients with three types of leukemia.

Related Summaries